Cancer Diagnostics 2016-2020: Emerging Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Supplier Shares, Country Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review
This comprehensive seven-country report contains 650 pages, 150 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the global coagulation testing market during the next five years.
The report explores business and technological trends in the US, Europe (France, Germany, Italy, Spain, UK) and Japan; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.
The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in chromagenic substrates, monoclonal antibodies, immunoassays, molecular diagnostics, computers and laboratory automation will radically change the global coagulation diagnostics practice during the next five years.
New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation. Coagulation testing will also become more stand ardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating additional opportunities and challenges for suppliers.
Activated Clotting Time (ACT) (1), Activated Protein C Resistance,Activated PTT (APTT), Alpha 2-Antiplasmin, Antithrombin III, Bleeding Time, D-Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII, Factor IX,Factor Ixa, Factor X (Stuart Factor), Factor Xa, Factor XI, Factor XII, Factor XIII, Fibrin Degradation Products, Fibrinogen, Fletcher Factor/Pre-Kallikrein Factor Activation, Heparin/Anti-Factor Xa, Heparin-Induced Thrombocytopenia, Plasmin, Plasminogen, Plasminogen Activator Inhib., Platelet Function/Aggregation, Protein C, Protein S, Prothrombin Mutation, Prothrombin Time (PT), Reptilase Time, Thrombin Time, Von Willebrand 's Factor Fav/Ag, and others.
France, Germany, Italy, Japan, Spain, UK, USA
Sales and Market Share Analysis
- Sales and market shares of major instrument and reagent suppliers.
- Extensive strategic profiles ofmajor suppliers and emerging market entrants
Market Segmentation Analysis
- Comprehensive marketsegmentation analysis, including:
- Hospitals - Commercial/Private Laboratories - Physician Offices - Ambulatory Care Centers - Test volume forecasts for over 40 major procedures,by country and market segment.
Current and Emerging Products
- Review of established and emerging procedures. - Comparison of automated and semi-automatedanalyzers from Diagnostica Stago, Helena, IL, Siemens, Sysmex and other suppliers.
- Analysis of current and emerging technologies and their potential market applications. - Comprehensive lists of companies developingor marketing new technologies and products by test.
Worldwide Market Overview
- Estimates of facilities performing coagulation testsby country. - Test volume and sales projections by country.
- Product development and business expansion opportunities with significant market appeal. - “Ideal” product models with tentativeprices and operating characteristics. - Alternative market penetrationstrategies for instrument and reagent suppliers. - Potential market entry barriers and risks.
650 pages and 150 table's
Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook